We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation<sup>1</sup>.
- Authors
Schnuelle, Peter; Lorenz, Dietmar; Mueller, Alexander; Trede, Michael; Van Der Woude, Fokko Johannes
- Abstract
Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation. Background. Epidemiological data implicate that renal transplants from living unrelated donors result in superior survival rates as compared with cadaveric grafts, despite a higher degree of human lymphocyte antigen (HLA) mismatching. We undertook a center-based case control study to identify donor-specific determinants affecting early outcome in cadaveric transplantation. Methods. The study database consisted of 152 consecutive cadaveric renal transplants performed at our center between June 1989 and September 1998. Of these, 24 patients received a retransplant. Donor kidneys were allocated on the basis of prospective HLA matching according to the Eurotransplant rules of organ sharing. Immunosuppressive therapy consisted of a cyclosporine-based triple-drug regimen. In 67 recipients, at least one acute rejection episode occurred during the first month after transplantation. They were taken as cases, and the remaining 85 patients were the controls. Stepwise logistic regression was done on donor-specific explanatory variables obtained from standardized Eurotransplant Necrokidney reports. In a secondary evaluation, the impact on graft survival in long-term follow-up was further measured by applying a Cox regression model. The mean follow-up of all transplant recipients was 3.8 years (sd 2.7 years). Results. Donor age [odds ratio (OR) 1.05; 95% CI, 1.02 to 1.08], traumatic brain injury as cause of death (OR 2.75; 95% CI, 1.16 to 6.52), and mismatch on HLA-DR (OR 3.0; 95% CI, 1.47 to 6.12) were associated with an increased risk of acute rejection, whereas donor use of dopamine (OR 0.22; 95% CI, 0.09 to 0.51) and/or noradrenaline (OR 0.24; 95% CI, 0.10 to 0.60) independently resulted in a significant beneficial effect. In the multivariate Cox regression analysis, both donor treatment with dopamine (HR 0.44; 95% CI, 0.22 to 0.84) and...
- Subjects
CADAVER homografts; VASOCONSTRICTORS
- Publication
Kidney International, 1999, Vol 56, Issue 2, p738
- ISSN
0085-2538
- Publication type
Article
- DOI
10.1046/j.1523-1755.1999.00567.x